Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1496

Cellular and Animal Model for Infantile Hemangioma

Inventors: Joyce Bischoff, Zia Khan, Elisa Boscolo, John Mulliken

Invention Types: Research Tool

Research Areas: Dermatology, Neonatology/Pediatric

Keywords: Animal Model (mouse), Cell Line

For More Information Contact:  Dietz, Ryan

 

Invention Description:

Infantile hemangiomas are the most common tumors of infancy. These non-cancerous vascular tumors appear within the first month of life and will continue to grow for up to 12 months. The tumors eventually begin to slowly regress over 1 to 7 years, but this period of involution and its extent are extremely variable. Most hemangiomas do not regress to an acceptable cosmetic level on their own. They occur most often in the head and neck region but they may occur anywhere on the skin or internal organs, and can lead to cardiac failure, hemorrhage and jaundice in addition to disfigurement. Dr. Bischoff and colleagues found that CD133+ cells from patient-derived hemangioma tissue formed hemangioma-like lesions when injected along with a matrix material in immunodeficient mice.

Applications:

The discovery by Dr. Bischoff and colleagues represent the first cellular and animal model of infantile hemangioma. The in vitro and in vivo model generated in Dr. Bischoff’s lab can be used to study vasculogenesis, angiogenesis, tissue remodeling, hemangioma formation and progression, as well as activity and mechanism of action of potential therapeutics for this common childhood tumor. Between 4% and 10% of Caucasian infants have at least one hemangioma; most remain small and pose no serious threat to the infant but about 10% of these become clinically significant The incidence increases to 1 in 5 in premature infants. Problematic hemangiomas are high sources of morbidity and can cause psychosocial complications. Current therapies include systemic or intralesional corticosteroids, vincristine, as well as laser and surgical interventions, and are used with variable results.

Competitive Advantages:

To date, there are no animal models that are able to accurately reflect human hemangiomas. The murine model from Dr. Bischoff's lab is the first model to recapitulate the unique evolution of this common tumor of infancy. These cellular and animal models represent powerful tools to study novel therapeutic modalities and gain insight into the biological phenomenon of vessel formation from progenitor cells.

Business Opportunity:

Non-exclusive license for research use

Key Publications: J. Clin. Invest. 118:2592-2599 (2008)

IPStatus: No Protection